TELA Bio Approves Inducement Grants for New Employees Under Nasdaq Rule 5635(c)(4)
TELA Bio, Inc. (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has recently announced that it has approved inducement grants for five newly-hired employees. The Compensation Committee of the Board of Directors of TELA Bio granted restricted stock units covering 5,800 shares of its common stock to these employees, with a grant date of February 21, 2024.
These inducement grants were made in accordance with the Nasdaq Rule 5635(c)(4) exception, as part of each individual’s employment compensation. The grants were provided to encourage and incentivize these employees to accept employment with TELA Bio.
TELA Bio’s focus lies in providing innovative solutions for optimizing clinical outcomes by prioritizing the preservation and restoration of a patient’s own anatomy. The company aims to revolutionize soft-tissue reconstruction techniques to enhance patient well-being.
Despite their recent inducement grants, TELA Bio has faced financial challenges. The company recorded a cumulative net loss of $44 million during the 12 months ending in the third quarter of 2023. This resulted in a negative return on investment (ROI) of -69.13%, highlighting the need for strategic advancements.
With the new inducement grants, TELA Bio aims to attract and retain talented individuals who can contribute to the company’s growth and success. By incentivizing employees with ownership stakes, TELA Bio seeks to align their interests with the long-term goals of the organization.
Comments